Can jakafi cause liver damage?

See the DrugPatentWatch profile for jakafi

Can Jakafi (ruxolitinib) damage the liver?

Yes. Jakafi can cause liver-related side effects. The main concern is elevated liver enzymes (which can indicate liver irritation or injury) and, less commonly, liver function problems. In clinical use, liver enzyme increases are monitored during treatment. [1][2]

What liver problems should patients watch for?

Liver-related warning signs users often look for include symptoms consistent with liver injury, such as:
- Yellowing of the skin or eyes (jaundice)
- Dark urine
- Severe fatigue or weakness
- Right upper belly pain
- Loss of appetite, nausea, or vomiting that is new or worsening

If any of these occur, patients should contact their clinician promptly. The prescribing information also emphasizes regular lab monitoring for liver tests. [1]

How common are liver enzyme elevations with Jakafi?

Liver enzyme elevations are a known risk and are typically detected through blood tests rather than symptoms alone. The label describes increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin, with dose-related patterns reported. [1][2]

What should clinicians do if liver tests rise?

Treatment adjustments may be needed depending on the severity of abnormal liver labs. Clinicians may:
- Increase monitoring frequency
- Hold therapy temporarily
- Reduce the dose
- Stop treatment if significant liver injury is suspected

These decisions are guided by the patient’s lab results and overall clinical picture. [1]

Are there people who are at higher risk?

Liver enzyme abnormalities can be more likely in people who already have liver impairment or other factors that stress the liver. The label includes guidance on liver-related considerations and how dosing/monitoring may change for patients with hepatic issues. [1][2]

Does Jakafi cause permanent liver damage?

Serious liver injury is uncommon, and most cases of enzyme elevations during treatment are identified early via monitoring and managed with dose adjustments. The prescribing information does not suggest that liver damage is guaranteed or usually permanent, but it does include warnings and the need for prompt management if significant abnormalities occur. [1]

Sources

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/
   
2. https://www.jakafi.com/ (Jakafi prescribing information / safety information)